Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Possible news release next week ?

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Feb 05, 2021 8:30pm

179 Views

Post# 32491314

RE:RE:Possible news release next week ?

Let's bring this back into reality for a second. High volume? We're talking ~5.5M shares with a valuation of ~$139k, so ~1% of outstanding shares. Anyone quoting % gain is dellusional, not hard to advance when the initial position was 0.001c LOL.

People aren't dropping like flies, good god, get a grip. The average age of Covid deaths last I checked is 82 and they tend to have comorbidities, vascular, cardiac, obesity etc.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property